Evaluation of dual therapy in real life setting in treatment-naive turkish patients with hcv infection: A multicenter, retrospective study

Basit Öğe Kaydı
dc.contributor.authorGürbüz, Yunus
dc.contributor.authorTülek, Necla Eren
dc.contributor.authorTütüncü, Emin Ediz
dc.contributor.authorKoruk, Süda Tekin
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemirtürk, Neşe
dc.contributor.authorKınıklı, Sami
dc.contributor.authorKaya, Ali
dc.contributor.authorYıldırmak, Taner
dc.contributor.authorSüer, Kaya
dc.contributor.authorKorkmaz, Fatime
dc.contributor.authorUral, Onur
dc.contributor.authorAkhan, Sıla
dc.contributor.authorGünal, Özgür
dc.contributor.authorTuna, Nazan
dc.contributor.authorKöse, Şükran
dc.contributor.authorGönen, İbak
dc.contributor.authorÖrmen, Bahar
dc.contributor.authorTürker, Nesrin
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorTuncer, Günay
dc.contributor.authorBulut, Cemal
dc.contributor.authorSırmatel, Fatma
dc.contributor.authorUlçay, Asım
dc.contributor.authorKaragöz, Ergenekon
dc.contributor.authorTosun, Derviş
dc.contributor.authorŞener, Alper
dc.contributor.authorAynıoğlu, Aynur
dc.contributor.authorAltunok, Elif Sargın
dc.date.accessioned2020-03-26T19:24:04Z
dc.date.available2020-03-26T19:24:04Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionConference of the Asian-Pacific-Association-for-the-Study-of-the-Liver (APASL) -- MAR 12-15, 2014 -- Brisbane, AUSTRALIAen_US
dc.description.abstractBackground: Before the introduction of direct-acting antivirals in the treatment of chronic hepatitis C patients, the combination of peginterferon alpha and ribavirin was the standard therapy. Observational studies that investigated sustained virological response (SVR) rates by these drugs yielded different outcomes. Aims: The goal of the study was to demonstrate real life data concerning SVR rate achieved by peginterferon alpha plus ribavirin in patients who were treatment-naive. Study Design: A multicenter, retrospective observational study. Methods: The study was conducted retrospectively on 1214 treatment naive-patients, being treated with peginterferon alpha-2a or 2b plus ribavirin in respect of the current guidelines between 2005 and 2013. The patients' data were collected from 22 centers via a standard form, which has been prepared for this study. The data included demographic and clinical characteristics (gender, age, body weight, initial Hepatitis C virus RNA (HCV RNA) level, disease staging) as well as course of treatment (duration of treatment, outcomes, discontinuations and adverse events). Renal insufficiency, decompensated liver disease, history of transplantation, immunosuppressive therapy or autoimmune liver disease were exclusion criteria for the study. Treatment efficacy was assessed according to the patient's demographic characteristics, baseline viral load, genotype, and fibrosis scores. Results: The mean age of the patients was 50.74 (+/- 0.64) years. Most of them were infected with genotype 1 (91.8%). SVR was achieved in 761 (62.7%) patients. SVR rate was 59.1% in genotype 1, 89.4% in genotype 2, 93.8% in genotype 3, and 33.3% in genotype 4 patients. Patients with lower viral load yielded higher SVR (65.8% vs. 58.4%, p=0.09). SVR rates according to histologic severity were found to be 69.3%, 66.3%, 59.9%, 47.3%, and 45.5% in patients with fibrosis stage 0, 1, 2, 3 and 4, respectively. The predictors of SVR were male gender, genotype 2/3, age less than 45 years, low fibrosis stage, low baseline viral load and presence of early virological response. SVR rates to each peginterferon were found to be similar in genotype 1/4 although SVR rates were found to be higher for peginterferon alpha-2b in patients with genotype 2/3. The number of patients who failed to complete treatment due to adverse effects was 33 (2.7%). The number of patients failed to complete treatment due to adverse effects was 33 (2.7%). Conclusion: Our findings showed that the rate of SVR to dual therapy was higher in treatment-naive Turkish patients than that reported in randomized controlled trials. Also peginterferon alpha-2a and alpha-2b were found to be similar in terms of SVR in genotype 1 patients.en_US
dc.description.sponsorshipAsian Pacific Assoc Study Liveren_US
dc.identifier.citationGürbüz, Y., Tülek, N. E., Tütüncü, E. E., Koruk, S. T., Aygen, B., Demirtürk, Kınıklı, S., Kaya, A., Yıldırma, T., Süer, K., Korkmaz, F., Ural, O., Akhan, S., Günal, Ö., Tuna, N., Köse, Ş., Gönen, İ., Örmen, B., Türker, N., Saltoğlu, N., Batırel, A., Tuncer, G., Bulut, C., Sırmatel, F., Ulçay, A., Karagöz, E., Tosun, D., Şener, A., Aynıoğlu, A., Altunok, E. S. (2016). Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Medical Journal, 33(1), 18-26.
dc.identifier.doi10.5152/balkanmedj.2015.15859en_US
dc.identifier.endpage26en_US
dc.identifier.issn2146-3123en_US
dc.identifier.issn2146-3131en_US
dc.identifier.issue1en_US
dc.identifier.pmid26966614en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage18en_US
dc.identifier.urihttps://dx.doi.org/10.5152/balkanmedj.2015.15859
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33571
dc.identifier.volume33en_US
dc.identifier.wosWOS:000370967500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUral, Onur
dc.language.isoenen_US
dc.publisherGALENOS YAYINCILIKen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHepatitis Cen_US
dc.subjectpeginterferon alpha-2aen_US
dc.subjectpeginterferon alpha-2ben_US
dc.subjectribavirinen_US
dc.subjecttherapyen_US
dc.titleEvaluation of dual therapy in real life setting in treatment-naive turkish patients with hcv infection: A multicenter, retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yunus GÜRBÜZ.pdf
Boyut:
342.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji /Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu